188 related articles for article (PubMed ID: 24418837)
21. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
[TBL] [Abstract][Full Text] [Related]
22. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
[TBL] [Abstract][Full Text] [Related]
23. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
Link-Gelles R; Taylor T; Moore MR;
Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
[TBL] [Abstract][Full Text] [Related]
24. Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009.
Wortham JM; Zell ER; Pondo T; Harrison LH; Schaffner W; Lynfield R; Thomas A; Reingold A; Bennett NM; Petit S; Aragon D; Bareta J; Juni BA; Farley MM; Beall B; Moore MR
Clin Infect Dis; 2014 May; 58(9):1250-7. PubMed ID: 24585565
[TBL] [Abstract][Full Text] [Related]
25. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
De Wals P; Lefebvre B; Deceuninck G; Longtin J
Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
[TBL] [Abstract][Full Text] [Related]
26. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
[TBL] [Abstract][Full Text] [Related]
27. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
[TBL] [Abstract][Full Text] [Related]
28. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
29. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine.
Poehling KA; Talbot TR; Griffin MR; Craig AS; Whitney CG; Zell E; Lexau CA; Thomas AR; Harrison LH; Reingold AL; Hadler JL; Farley MM; Anderson BJ; Schaffner W
JAMA; 2006 Apr; 295(14):1668-74. PubMed ID: 16609088
[TBL] [Abstract][Full Text] [Related]
30. Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.
Vestjens SMT; Sanders EAM; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
Vaccine; 2019 Oct; 37(43):6558-6565. PubMed ID: 31500963
[TBL] [Abstract][Full Text] [Related]
31. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
[TBL] [Abstract][Full Text] [Related]
32. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
[TBL] [Abstract][Full Text] [Related]
34. Trends in Invasive Pneumococcal Disease in Cancer Patients After the Introduction of 7-valent Pneumococcal Conjugate Vaccine: A 20-year Longitudinal Study at a Major Urban Cancer Center.
Lee YJ; Huang YT; Kim SJ; Kerpelev M; Gonzalez V; Kaltsas A; Papanicolaou G
Clin Infect Dis; 2018 Jan; 66(2):244-253. PubMed ID: 29020313
[TBL] [Abstract][Full Text] [Related]
35. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
[TBL] [Abstract][Full Text] [Related]
36. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
Johnson DR; D'Onise K; Holland RA; Raupach JC; Koehler AP
Vaccine; 2012 Mar; 30(12):2206-11. PubMed ID: 22273663
[TBL] [Abstract][Full Text] [Related]
38. Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance.
; Mackenzie GA; Hill PC; Jeffries DJ; Ndiaye M; Sahito SM; Hossain I; Uchendu U; Ameh D; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Ahameefula E; Fombah AE; Adeshola B; Lobga BG; Saha D; Mackenzie R; Odutola A; Plumb ID; Akano A; Ebruke BE; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UN; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Fofana S; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2021 Sep; 21(9):1293-1302. PubMed ID: 34280357
[TBL] [Abstract][Full Text] [Related]
39. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
40. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.
Hsu KK; Shea KM; Stevenson AE; Pelton SI;
Pediatr Infect Dis J; 2010 Apr; 29(4):289-93. PubMed ID: 19935447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
